-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AOC-1044 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AOC-1044 in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AOC-1044 in Duchenne Muscular Dystrophy Drug Details: AOC-1044 is under...
-
Product Insights
NewNet Present Value Model: Avidity Biosciences Inc’s AOC-1020
Empower your strategies with our Net Present Value Model: Avidity Biosciences Inc's AOC-1020 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Avidity Biosciences Inc’s Delpacibart etedesiran
Empower your strategies with our Net Present Value Model: Avidity Biosciences Inc's Delpacibart etedesiran report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delpacibart Etedesiran in Myotonic Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delpacibart Etedesiran in Myotonic Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delpacibart Etedesiran in Myotonic Dystrophy Drug Details: Delpacibart etedesiran (AOC-1001)...
-
Product Insights
NewNet Present Value Model: Ultragenyx Pharmaceutical Inc’s Setrusumab
Empower your strategies with our Net Present Value Model: Ultragenyx Pharmaceutical Inc's Setrusumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...
-
Product Insights
NewFacioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2024
Empower your strategies with our Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2024 report and make more profitable business decisions. Facioscapulohumeral muscular dystrophy (FSHD) typically manifests with varying degrees of facial, scapular stabilizer, and dorsiflexor muscle weakness. Progression is slow, with about 20% of individuals eventually requiring a wheelchair, though life expectancy remains unaffected. Diagnosis of FSHD1 involves identifying a heterozygous pathogenic contraction of the D4Z4 repeat array on chromosome 4q35 with a chromosome 4 permissive haplotype. FSHD2 diagnosis is...
-
Product Insights
NewMyotonic Dystrophy – Drugs In Development, 2024
Empower your strategies with our Myotonic Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Myotonic dystrophy (DM), also known as dystrophia myotonica, is a group of genetic disorders characterized by progressive muscle weakness, myotonia (delayed relaxation of muscles after contraction), and various multi-systemic manifestations. It is one of the most common forms of adult-onset muscular dystrophy and can affect multiple organs and systems in the body. There are two main types of myotonic dystrophy, DM1 and...
-
Product Insights
NewColon Carcinoma – Drugs In Development, 2024
Empower your strategies with our Colon Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Colon carcinoma is a type of cancer that affects the large intestine, which includes the colon and the rectum. It is one of the most common cancers worldwide and can cause symptoms such as blood in the stool, weight loss, and fatigue. Colon carcinoma usually develops from benign growths called polyps that form on the inner lining of the colon or rectum....